Kronox Lab Sciences Gets SEBI Nod For IPO


The offer represents upto 26 per cent of the paid-up equity share capital of Kronox Lab Sciences


FinTech BizNews Service   

Mumbai, April 19, 2024:  Vadodara based Kronox Lab Sciences (“Kronox” or “Company”), manufacturer of high-purity

speciality fine chemicals, has received capital markets regulator Sebi's nod to launch Initial Public

Offering (IPO).

Under the Offer for Sale, up to 96 lakhs equity shares will be offloaded jointly by the promoters

namely Jogindersingh Jaswal, Ketan Ramani and Pritesh Ramani. The offer represents upto 26 per

cent of the paid-up equity share capital of Kronox Lab Sciences.

Kronox’s High Purity Speciality Fine Chemicals portfolio has more than 185 products. The products

are used mainly for applications across pharmaceuticals, nutraceuticals, biotech, food, animal

health, scientific research, agrochemicals, personal care, amongst others. Kronox exports to more

than 20 countries with major exports to USA, United Kingdom, Mexico, Australia, Egypt.

The Company has 3 manufacturing facilities and Research, Development and Testing (“RDT”)

laboratory, situated in Vadodara, Gujarat. Additionally, the Company has acquired land at Dahej,

Gujarat to set up a new manufacturing plant. The Company has more than 120 products under

various phases of research and development.

Completely debt free business, Kronox works at more than 15% Post tax profit margin. Interestingly,

Kronox has a formidable track record of two buy backs and a bonus issue in the previous five

financial years.

For Fiscal 2023, Kronox generated consolidated revenue from operations of Rs. 95.6 crores growing

at CAGR of 23.70% over Fiscal 2021 to 2023. The Company had EBITDA of Rs. 22.0 crores and EBITDA

margin of 23.01%. The Company’s profit after tax for Fiscal 2023 was Rs. 16.6 crores with PAT margin

of 17.04%. The Company’s Return on Equity (RoE) and Return on Capital Employed (RoCE) stood at

37.2% and 49.9% respectively for Fiscal 2023.

Kronox Lab Sciences, which filed draft red herring prospectus dated January 25, 2024 with the

market regulator Sebi, obtained its observation letter on April 12, 2024, an update with the

Securities and Exchange Board of India (Sebi) showed.

Pantomath Capital Advisors Private Limited is the sole book-running lead manager. The Company’s

equity shares are proposed to be listed on the BSE and NSE.

Cookie Consent

Our website uses cookies to provide your browsing experience and relavent informations.Before continuing to use our website, you agree & accept of our Cookie Policy & Privacy